This technical report defines the U131 High-Resolution Structural Screening Framework RC. It extends the U131 Global Ethnobotanical Structural Screening Framework by adding rule-delta governance, CompoundGraph proxies, dynamic pathway and target-proxy topology, cryptographic blind-registry governance, and a finite-geometric address monograph layer.The framework refines structural screening resolution while preserving explicit claim boundaries. Rule-delta candidates are generated only under eligibility gates and remain quarantined unless future audited releases permit them. CompoundGraph proxies represent molecular topology for structural complementarity, redundancy, risk-substructure routing, and no-call handling, but not binding affinity or pharmacological effect. Dynamic pathway and target-proxy topology supports network coherence and conflict detection without asserting biological causality. Cryptographic registry governance strengthens candidate-freeze verification through digest chains and timestamp protocols. The finite-geometric address layer formalizes K48, codon-amino-acid, Fano, octonion, H4, and E8 address annotations as non-predictive structural metadata.Across the v4001-v5000 high-resolution audit sequence, 938,900 of 938,900 computational governance checks passed. These checks assess boundary preservation, digest consistency, shadow replay, non-leakage, no-posthoc-retuning compliance, no-call routing, and quarantine behavior. They do not constitute evidence of clinical efficacy, prescribing suitability, dosage guidance, human safety, binding affinity, pharmacological activity, human use, or drug development.
Takada et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: